Juno Urges Fed. Circ. To Undo 'Mischief' In Wiping $1B IP Win
Bristol-Myers Squibb subsidiary Juno Therapeutics is asking the full Federal Circuit to reconsider its reversal of a $1.1 billion judgment against Gilead's Kite Pharma Inc., slamming the "mischief" caused by the...To view the full article, register now.
Already a subscriber? Click here to view full article